CHINARES PHARMA Subsidiary CR Pharmaceutical Commercial Completes RMB1.80 Billion First-Tranche 2026 Bond Issue at 1.70% Coupon

Bulletin Express03-27

Hong Kong, 27 March 2026 — China Resources Pharmaceutical Group Limited (stock name: CHINARES PHARMA) announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial, has finalised the public issuance of the first tranche of its 2026 corporate bonds in mainland China.

The tranche raised RMB1.80 billion, carries a three-year tenor and bears a fixed coupon of 1.70% per annum. The offering forms part of a broader programme approved by the China Securities Regulatory Commission, allowing CR Pharmaceutical Commercial to issue up to RMB20.00 billion of bonds to qualified domestic investors.

Net proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant laws and regulations.

The company reiterated its usual caution for shareholders and potential investors when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165998199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165998199","market":"us","top_or_hot":-1,"title":"CHINARES PHARMA Subsidiary CR Pharmaceutical Commercial Completes RMB1.80 Billion First-Tranche 2026 Bond Issue at 1.70% Coupon","media":"Bulletin Express","content":"<p>Hong Kong, 27 March 2026 — China Resources Pharmaceutical Group Limited (stock name: CHINARES PHARMA) announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial, has finalised the public issuance of the first tranche of its 2026 corporate bonds in mainland China.</p>\n<p>The tranche raised RMB1.80 billion, carries a three-year tenor and bears a fixed coupon of 1.70% per annum. The offering forms part of a broader programme approved by the China Securities Regulatory Commission, allowing CR Pharmaceutical Commercial to issue up to RMB20.00 billion of bonds to qualified domestic investors.</p>\n<p>Net proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant laws and regulations.</p>\n<p>The company reiterated its usual caution for shareholders and potential investors when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA Subsidiary CR Pharmaceutical Commercial Completes RMB1.80 Billion First-Tranche 2026 Bond Issue at 1.70% Coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA Subsidiary CR Pharmaceutical Commercial Completes RMB1.80 Billion First-Tranche 2026 Bond Issue at 1.70% Coupon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-27 20:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 27 March 2026 — China Resources Pharmaceutical Group Limited (stock name: CHINARES PHARMA) announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial, has finalised the public issuance of the first tranche of its 2026 corporate bonds in mainland China.</p>\n<p>The tranche raised RMB1.80 billion, carries a three-year tenor and bears a fixed coupon of 1.70% per annum. The offering forms part of a broader programme approved by the China Securities Regulatory Commission, allowing CR Pharmaceutical Commercial to issue up to RMB20.00 billion of bonds to qualified domestic investors.</p>\n<p>Net proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant laws and regulations.</p>\n<p>The company reiterated its usual caution for shareholders and potential investors when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1165998199","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165998199","pubTimestamp":1774614473,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 27 March 2026 — China Resources Pharmaceutical Group Limited (stock name: CHINARES PHARMA) announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial, has finalised the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药子公司华润医药商业完成2026年第一期18亿元债券发行，票面利率为1.70%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"Hong Kong, 27 March 2026 — China Resources Pharmaceutical Group Limited (stock name: CHINARES PHARMA) announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial, has finalised the public issuance of the first tranche of its 2026 corporate bonds in mainland China.\nThe tranche raised RMB1.80 billion, carries a three-year tenor and bears a fixed coupon of 1.70% per annum. The offering forms part of a broader programme approved by the China Securities Regulatory Commission, allowing CR Pharmaceutical Commercial to issue up to RMB20.00 billion of bonds to qualified domestic investors.\nNet proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant laws and regulations.\nThe company reiterated its usual caution for shareholders and potential investors when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165998199","isCrawlerRequest":true}